We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
+12.87%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
–
AUM
$568M
AUM Growth
-$26.8M
Cap. Flow
-$86.9M
Cap. Flow %
-15.28%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$85.9M
2
FIRY
Firy Inc
FIRY
+$947K

Sector Composition

Rank Sector Weight
1 Communication Services 89.34%
2 Healthcare 10.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FIRY
1
Firy Inc
FIRY
$144M
$498M 87.54%
1,145,493
-2,653
-0.2% -$947K
SURF
2
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$22M 3.87%
2,945,453
– –
SPRO icon
3
Spero Therapeutics
SPRO
$66.6M
$19.2M 3.38%
1,376,968
– –
SYBX
4
DELISTED
Synlogic
SYBX
$10.3M 1.82%
176,798
– –
SNAP icon
5
Snap
SNAP
$8.48B
$10.2M 1.8%
150,160
– –
COGT icon
6
Cogent Biosciences
COGT
$6.64B
$7.44M 1.31%
916,832
– –
NTLA icon
7
Intellia Therapeutics
NTLA
$1.5B
$1.62M 0.28%
10,000
-1,103,376
-99% -$85.9M

Similar funds

EEPIS
Evolution Equity Partners II SARL Luxembourg $11.8M AUM 63.6% 1-Year Est. Return
LM
Lockheed Martin Bethesda, Maryland $12.1M AUM 46.13% 1-Year Est. Return
HMP9
Highland Management Partners 9 Cambridge, Massachusetts $12.6M AUM 85.13% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
AEM
ACON Equity Management Washington, District of Columbia $13.8M AUM 62.17% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
AR
Acacia Research New York $14.1M AUM 50.98% 1-Year Est. Return
MM
Malka Meyer $8.77M AUM 64.77% 1-Year Est. Return

Atlas Venture Associates IX's Q2 2021 Portfolio in Review

As of Q2 2021, Atlas Venture Associates IX held 7 positions worth $568M, down 4.5% from $595M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Associates IX withdrew a net $86.9M in Q2 2021, reducing 2 holdings. Its largest reduction was Intellia Therapeutics, cutting an estimated $85.9M.

By sector, the portfolio is most concentrated in Communication Services at 89% of assets, up from 75% a quarter earlier, followed by Healthcare.

  • Atlas Venture Associates IX's biggest Q2 2021 reduction was Intellia Therapeutics, cutting an estimated $85.9M.
  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $568M portfolio in Q2 2021.
  • Atlas Venture Associates IX opened 0 new positions and closed 0 in Q2 2021.
  • Atlas Venture Associates IX's portfolio value fell 4.5% quarter-over-quarter to $568M.

Based on Atlas Venture Associates IX's 13F filing for Q2 2021, filed 11 Aug 2021.